Bimatoprost 0.01%

DRUG9 trials

Sponsors

Allergan, Northwestern University

Conditions

GlaucomaGlaucoma, Open-AngleGlaucoma, Primary Open AngleIntraocular PressureNail Growth CessationOcular Hypertension

Phase 3

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

CompletedNCT01830140

AllerganGlaucoma, Ocular Hypertension

Start: 2013-07-31End: 2014-05-31Updated: 2015-05-06

Phase 4

A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

CompletedNCT01594970

AllerganGlaucoma, Open-Angle, Ocular Hypertension

Start: 2012-03-31End: 2013-01-31Updated: 2014-01-28

A Study of LUMIGAN® RC in the Clinical Setting

CompletedNCT01833741

AllerganGlaucoma, Primary Open Angle, Ocular Hypertension

Start: 2009-12-31End: 2011-03-31Updated: 2013-09-26

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

CompletedNCT01881126

AllerganGlaucoma, Ocular Hypertension

Start: 2013-06-30End: 2014-10-31Updated: 2015-11-30

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

CompletedNCT02097719

AllerganGlaucoma, Ocular Hypertension

Start: 2014-05-31End: 2014-12-31Updated: 2016-01-14

Unknown Phase

Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

CompletedNCT01628588

AllerganGlaucoma, Open-Angle, Ocular Hypertension

Start: 2010-03-31End: 2010-12-31Updated: 2012-09-24

A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

CompletedNCT01632423

AllerganGlaucoma, Open-Angle, Ocular Hypertension

Start: 2010-02-28End: 2010-11-30Updated: 2012-09-21

A Study of Bimatoprost 0.01% in the Clinical Setting

CompletedNCT01814761

AllerganGlaucoma, Primary Open Angle, Ocular Hypertension

Start: 2013-05-31End: 2014-08-31Updated: 2015-10-26

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

CompletedNCT02448043

Northwestern UniversityIntraocular Pressure, Nail Growth Cessation

Start: 2015-06-04End: 2016-05-06Updated: 2019-12-13

Related Papers

Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.

2016-09-154 citations

Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting

BMC Ophthalmology2014-12-018 citations